Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Stereotactic Radiation in Metastatic Breast Cancer Brain Metastases
NCT03807765Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Jan 2019
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab in breast cancer and brain metastases, sponsored by Moffitt Cancer Center. Primary endpoint: Number of Participants who experience Dose Limiting Toxicities at 8 weeks. Started Jan 2019; status: completed.
02
Drugs
03
Conditions
breast cancerbrain metastases
Beyond the preview
Go deeper on NCT03807765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03807765.